Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors

NCT03190174 is registered in ClinicalTrials.gov with Sarcoma Oncology Research Center, LLC as lead sponsor.

NCT NCT03190174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
Lead sponsor
Sarcoma Oncology Research Center, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
August 24, 2017
Completion date
December 2, 2021
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chordoma, classical hodgkin lymphoma, colorectal cancer, desmoid tumor, epithelioid sarcoma, ewing sarcoma, hepatocellular carcinoma, melanoma, mtor activating mutation, non small cell lung cancer, pecoma, renal cell carcinoma, squamous cell carcinoma, urothelial carcinoma